Karyopharm公布2026年第一季度财务业绩并完成子宫内膜癌三期试验患者招募

美股速递
May 14

Karyopharm Therapeutics Inc. (KPTI) 近日宣布了其2026年第一季度的财务业绩,并同步披露了一项关键临床进展:公司已成功完成其针对子宫内膜癌的三期临床试验的患者招募工作。

这一进展标志着公司核心管线药物selinexor在拓展新适应症方面迈出了重要一步。子宫内膜癌是女性生殖系统常见的恶性肿瘤,此次三期试验的顺利完成,为后续获取关键疗效数据、寻求监管批准奠定了坚实基础。

与此同时,公司公布的2026年第一季度财务数据,为投资者评估其当前运营状况与资金储备提供了最新依据。在推进多项后期临床研究的同时,公司的财务状况与研发里程碑共同构成了市场关注的核心焦点。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10